Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Has results × ALK-positive Advanced NSCLC × brigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Conditions

Lung Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma 2 ALK-positive Advanced NSCLC 2 Neoplasms 1 Lymphoma, Large-Cell, Anaplastic 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Brain Neoplasms 1 Adenocarcinoma 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed

103 enrolled 23 charts

ALK-positive Advanced NSCLC

NCT03410108 2024-05-08

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Takeda

Phase 2 Completed

104 enrolled 22 charts

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡